Name: Legend Biotech CEO (LEGN) on JNJ Partnership & Rapidly Scaling Cancer Drug Revenue
Uploaded: 2025-12-05T21:11:36.512-06:00
Duration: 6 min 4 s
Description: Dr. Ying Huang, CEO of Legend Biotech (LEGN), explains the work his company does on white blood cell cancer. They grew revenue from the drug 84% last quarter to over $500 million, and expect to turn a profit in 2026. He discusses their partnership with Johnson & Johnson (JNJ), international expansion, and the research they’re conducting.

Don’t miss the go-to resource for pre-market action from the floorof the New York Stock Exchange. Join Diane King Hall for breaking economic news, expert analysis, technical insights, and real-timetrading strategies.

Morning Movers

“Opening Bell with Nicole Petallides" is Schwab Network’s flagship new morning show—broadcast live from the floor of the New York Stock Exchange—and built from the ground up to serve the active trader, the tactical investor, and the market-curious viewer who wants more than just headlines.

Opening Bell With Nicole Petallides

Sam Vadas takes traders beyond the headlines with a sharp focus on the macro drivers, sector rotations, and global forces shaping the day’s market action. From breaking down U.S. and international economic data to analyzing sector performance and cross-asset moves, Morning Trade Live delivers the context traders need to understand the “why” behind early trading activity.

Morning Trade Live

After the dust settles from the opening bell, Trading 360 with Marley Kayden features Wall Street’s best traders, analysts and technicians to break down sectors and stocks moving markets. Trading 360 focuses on disruptive companies and new technologies driving market headlines while providing investors a 360-degree actionable approach to trading.

Trading 360

Host Diane King Hall teams up with veteran traders Tom White and Kevin Hincks to break down live market moves and deliver actionable trade ideas in real time. From options strategies and volatility plays to earnings reactions, they bring in market specialists, analysts, and guests to give active traders the setups and strategies they can use right now.

Fast Market

The future of trading is here on Next Gen Investing. Alex Coffey and Jenny Horne take viewers through the markets from a unique perspective to help new investors pursue their financial goals. Next Gen Investing will explore various trading strategies while highlighting trending names and under the radar stocks in the market, while walking investors through real-time example trades.

Next Gen Investing

The Watch List with Nicole Petallides offers investors a midday look at the most relevant stocks, sectors and commodities. Petallides hosts a panel of experts ranging from industry-leading CEOs, analysts and Wall Street influencers to discuss pressing topics moving the market in real-time. The Watch List provides viewers with a midpoint status update for the end of the trading day and beyond.

The Watch List

Market on Close is Schwab Network’s signature end-of-day show—live from Wall Street and Chicago—where market intel meets real-time momentum. With Sam Vadas at the NYSE and Marley Kayden anchoring from Chicago HQ, we connect the dots between traders, catalysts, and tomorrow’s opening bell.&nbsp;

Market On Close

Market Overtime takes a break from the day-to-day news cycle and explores global financial trends with veteran investors and leading market minds. The show is a conversation looking at what is driving headlines globally, and what these trends mean for markets, the economy, and your financial future. Tune in to Market Overtime to get a new perspective on investing.

Market Overtime

Ever wonder what&nbsp;really&nbsp;makes a trader tick? Watch as a renowned neuroscientist takes you inside the minds of some of the most brilliant traders so you can discover ways you might apply their thinking to your own strategies. Presented by our broker-dealer affiliate, Charles Schwab &amp; Co., Inc., member SIPC, a subsidiary of The Charles Schwab Corporation,&nbsp;Inside the Mind of a Trader&nbsp;uses a mixture of questions and experiments to explore the mindset of three seasoned traders.Episodes premiere weekly starting Tuesday, September 3, 2024.

Inside the Mind of a Trader

Instead of sitting on the sidelines, take control of your financial future by watching Your First Trade. Host Ben Watson, Sr. Manager, Education Coach&nbsp;takes you on an educational journey where you can discover fundamental trading concepts and how to navigate the thinkorswim platform from Charles Schwab &amp; Co., Inc, member FINRA/SIPC, a subsidiary of The Charles Schwab Corporation. Your First Trade program content is presented by Charles Schwab &amp; Co., Inc. a broker/dealer, for educational purposes only.

Your First Trade

     

The Wrap is a nightly recap show, delivering the day’s top market headlines and most insightful interviews from Schwab Network's daily market coverage. Airing daily at 7pm ET, it highlights key takeaways from the trading session, expert analysis, and actionable ideas from the network’s best conversations—giving investors a concise, informative look at what moved the markets and what to watch next.

The Wrap

Schwab's Chief Investment Strategist, Liz Ann Sonders, brings her market insights and economic analysis to Schwab Coaching! Liz Ann Sonders and host Joe Mazzola will discuss her Market Commentary column and update you on the latest economic data and indicators that could impact the investing landscape. Join us and don't hesitate to ask your questions during this live, interactive segment.

Liz Ann Live

Join Schwab’s panel of experts on&nbsp;December&nbsp;11th for 2026 Market Outlook — your guide to the forces shaping stocks, global markets, inflation, rates, and more.&nbsp;Hear from experts on where the markets may be heading, spot opportunities, and see what could drive your portfolio next year.Tune in on&nbsp;Thursday,&nbsp;December&nbsp;11th&nbsp;at 7pm Eastern on Schwab Network.

Schwab 2026 Outlook

Daily insights for every investor

Schwab Network's Newsletters

Dr. Ying Huang, CEO of Legend Biotech (LEGN), explains the work his company does on white blood cell cancer. They grew revenue from the drug 84% last quarter to over $500 million, and expect to turn a profit in 2026. He discusses their partnership with Johnson &amp; Johnson (JNJ), international expansion, and the research they’re conducting.

Legend Biotech CEO (LEGN) on JNJ Partnership & Rapidly Scaling Cancer Drug Revenue

Expert commentary about top moving stocks, sectors, and commodities, along with CEO and analyst interviews.